S. Wegner

发表

Real‐world effectiveness of guselkumab in patients with psoriasis: Health‐related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial

M. Sticherling, S. Gerdes, F. Wiemers, 2021, The Journal of dermatology.

BJD_20963 773..781

A. Costanzo, I. Puig, C. Conrad, 2022 .

The biological basis of disease recurrence in psoriasis: a historical perspective and current models

E. Muñoz-Elías, A. Costanzo, C. Conrad, 2021, The British journal of dermatology.

Real‐world evidence from the non‐interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab

K. Asadullah, M. Sticherling, S. Gerdes, 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

Guselkumab is superior to fumaric acid esters in patients with moderate‐to‐severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active‐comparator‐controlled phase IIIb trial (POLARIS)

M. Sticherling, M. Sebastian, K. Eyerich, 2019, The British journal of dermatology.

IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)

K. Schäkel, K. Asadullah, E. Muñoz-Elías, 2021, BMJ Open.

Evolution of HCV patient characteristics and DAA regimens in the German Hepatitis C Registry (DHC-R) in 2014 and 2015

C. Sarrazin, S. Mauss, P. Buggisch, 2019, Zeitschrift für Gastroenterologie.

Effectiveness, safety and quality-of-life effects of guselkumab and ustekinumab in patients with psoriasis: Week 104 results from the non-interventional, prospective, German multicentre PERSIST study.

K. Asadullah, M. Sticherling, F. Kreimendahl, 2023, Journal of the European Academy of Dermatology and Venereology : JEADV.

083 Prolonged Q16W treatment interval of guselkumab is non-inferior to Q8W dosing for maintaining disease control in super responders: primary results from GUIDE at Week 68 in patients with psoriasis

K. Schäkel, K. Asadullah, K. Eyerich, 2022, Journal of Investigative Dermatology.

33830 Prognostic factors for early PASI 100 response in psoriasis patients treated with guselkumab: Results from the GUIDE study

K. Schäkel, K. Asadullah, K. Reich, 2022, Journal of the American Academy of Dermatology.

Pharmacological treatment of cardiovascular risk factors in patients with psoriasis: A Danish nationwide study

L. Skov, A. Egeberg, N. Loft, 2023, Journal of the European Academy of Dermatology and Venereology : JEADV.

Response Types and Factors Associated with Response Types to Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis from Two Randomized Clinical Trials

J. Buyze, S. Wegner, Diamant Thaçi, 2024, Dermatology and therapy.